December 18, 2013 - 8:31 a.m.
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
Printer Friendly Version 
December 16, 2013 - 8:31 a.m.
Health Canada Issues Notice of Compliance for Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Printer Friendly Version 
December 13, 2013 - 4:31 p.m.
U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen
Printer Friendly Version 
December 08, 2013 - 6:02 p.m.
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Printer Friendly Version 
December 07, 2013 - 6:31 p.m.
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia
Printer Friendly Version 
December 06, 2013 - 4:20 p.m.
U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Printer Friendly Version 
December 02, 2013 - 5:01 p.m.
Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3
Printer Friendly Version 
November 22, 2013 - 8:48 a.m.
European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovaldi® for the Treatment of Chronic Hepatitis C Infection
Printer Friendly Version 
November 18, 2013 - 9:18 a.m.
Gilead’s Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study
Printer Friendly Version 
November 18, 2013 - 8:00 a.m.
European Commission Approves Gilead’s Vitekta™, an Integrase Inhibitor for the Treatment of HIV-1 Infection
Printer Friendly Version 
November 12, 2013 - 4:34 p.m.
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13
Printer Friendly Version 
November 07, 2013 - 9:00 a.m.
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting
Printer Friendly Version 
November 02, 2013 - 9:02 a.m.
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
Printer Friendly Version 
November 02, 2013 - 9:02 a.m.
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients
Printer Friendly Version 
November 02, 2013 - 9:02 a.m.
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation
Printer Friendly Version 
October 29, 2013 - 4:03 p.m.
Gilead Sciences Announces Third Quarter 2013 Financial Results
Printer Friendly Version 
October 25, 2013 - 4:44 p.m.
FDA Advisory Committee Supports Approval of Gilead’s Sofosbuvir for Chronic Hepatitis C Infection
Printer Friendly Version 
October 22, 2013 - 5:01 p.m.
Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013
Printer Friendly Version 
October 16, 2013 - 3:11 a.m.
Gilead’s Single Tablet HIV Regimen Stribild® Demonstrates Durable Viral Suppression Through Three Years of Therapy
Printer Friendly Version 
October 09, 2013 - 4:16 p.m.
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit
Printer Friendly Version 
September 25, 2013 - 4:31 p.m.
European Commission Approves Gilead Sciences’ Tybost™, a New Boosting Agent for HIV Therapy
Printer Friendly Version 
September 12, 2013 - 5:01 p.m.
Gilead’s Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase 2 Study
Printer Friendly Version 
September 11, 2013 - 4:16 p.m.
Gilead Submits New Drug Application to U.S. FDA for Idelalisib for the Treatment of Indolent Non-Hodgkin’s Lymphoma
Printer Friendly Version 
September 06, 2013 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
July 25, 2013 - 4:07 p.m.
Gilead Sciences Announces Second Quarter 2013 Financial Results
Printer Friendly Version 
July 18, 2013 - 4:32 p.m.
Gilead Sciences to Release Second Quarter 2013 Financial Results on Thursday, July 25, 2013
Printer Friendly Version 
June 17, 2013 - 4:30 p.m.
Gilead Sciences to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18
Printer Friendly Version 
June 17, 2013 - 4:00 a.m.
Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma
Printer Friendly Version 
June 10, 2013 - 4:31 p.m.
Gilead Sciences to Present at the Goldman Sachs 34th Annual Healthcare Conference on Tuesday, June 11
Printer Friendly Version 
June 07, 2013 - 5:21 p.m.
Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C
Printer Friendly Version 
May 28, 2013 - 4:05 p.m.
Gilead Sciences to Present at the Deutsche Bank 38th Annual Health Care Conference on Wednesday, May 29
Printer Friendly Version 
May 28, 2013 - 8:30 a.m.
European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection
Printer Friendly Version 
May 21, 2013 - 4:31 p.m.
European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
Printer Friendly Version 
May 17, 2013 - 4:06 p.m.
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
Printer Friendly Version 
May 15, 2013 - 6:31 p.m.
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
Printer Friendly Version 
May 14, 2013 - 4:06 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
Printer Friendly Version 
May 02, 2013 - 4:06 p.m.
Gilead Sciences Announces First Quarter 2013 Financial Results
Printer Friendly Version 
May 02, 2013 - 8:31 a.m.
Gilead Reports Interim Data From Phase 2 LONESTAR Study
Printer Friendly Version 
April 29, 2013 - 8:31 a.m.
Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat
Printer Friendly Version 
April 25, 2013 - 4:31 p.m.
Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013
Printer Friendly Version 
April 23, 2013 - 6:07 a.m.
Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C To Be Presented at 48th Annual EASL Meeting; Findings Published Online Today in The New England Journal of Medicine
Printer Friendly Version 
April 08, 2013 - 4:31 p.m.
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C
Printer Friendly Version 
March 26, 2013 - 8:31 a.m.
Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
Printer Friendly Version 
March 22, 2013 - 8:31 a.m.
European CHMP Adopts Positive Opinion for Stribild®, a Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen for the Treatment of HIV-1 Infection
Printer Friendly Version 
March 10, 2013 - 2:58 p.m.
Gilead’s Ranexa® Reduces Angina Frequency in Study of Chronic Angina Patients With Type 2 Diabetes
Printer Friendly Version 
March 05, 2013 - 12:16 p.m.
Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF)
Printer Friendly Version 
March 01, 2013 - 4:32 p.m.
Gilead Sciences to Present at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4
Printer Friendly Version 
February 25, 2013 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 19, 2013 - 11:06 p.m.
Gilead and Teva Reach Settlement Agreement in Viread® Patent Litigation
Printer Friendly Version 
February 19, 2013 - 9:25 a.m.
Gilead’s Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study
Printer Friendly Version 
February 15, 2013 - 6:47 p.m.
Gilead Issues a Voluntary Recall of One Lot of Vistide® (Cidofovir Injection) Due to Presence of Particulate Matter
Printer Friendly Version 
February 11, 2013 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 08, 2013 - 4:16 p.m.
Gilead Sciences Completes Acquisition of YM BioSciences
Printer Friendly Version 
February 04, 2013 - 4:07 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results
Printer Friendly Version 
February 04, 2013 - 8:31 a.m.
Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C
Printer Friendly Version 
January 28, 2013 - 4:31 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2012 Financial Results on Monday, February 4, 2013
Printer Friendly Version 
January 24, 2013 - 8:32 a.m.
Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV
Printer Friendly Version 
January 07, 2013 - 8:31 a.m.
Gilead Provides Update on Hepatitis C Development Programs
Printer Friendly Version 
January 04, 2013 - 4:31 p.m.
Gilead Sciences to Present at the 31st Annual JPMorgan Healthcare Conference on Monday, January 7
Printer Friendly Version 
NASDAQ (US Dollar)
$108.45
 Stock is Up 2.91 (2.76%)
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote